FAdV-4 ON1 Viral Vector for High-Titer Avian Vaccine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adenovirus-based veterinary vaccine vectors face limitations in replication efficiency and immunogenicity, particularly for avian pathogens, necessitating the development of new adenoviruses with enhanced characteristics for effective immunogenic applications.
Innovation Solution
A novel high-replication fowl adenovirus isolate, FAdV-4 ON1, is developed, which achieves a viral titer of at least 3 log10 in chickens and serves as a non-pathogenic viral vector with an exogenous nucleotide sequence coding for antigenic sites of concern, enabling improved immunogenic compositions for disease protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current adenovirus-based veterinary vaccine vectors are used, then vaccine delivery is achieved, but replication efficiency and immunogenicity are limited
Solution Approach 1:
The patent employs parameter changes by modifying the adenovirus vector system through the use of novel serotypes (FAdV-4 and FAdV-10) with altered replication characteristics. These serotype selections represent parameter changes in viral identity that directly impact both replication efficiency (achieving ≥3 log10 viral titer) and immunogenicity (eliciting protective immune responses), thereby resolving the contradiction between productivity and reliability.
2Reliability
If adenovirus vectors are used for vaccine delivery, then disease protection is achieved, but replication efficiency is insufficient
Solution Approach 1:
The patent resolves this contradiction by changing the viral serotype parameter from conventional adenoviruses to novel FAdV-4 and FAdV-10 isolates. These parameter changes result in vectors that simultaneously achieve high viral titers (≥3 log10) in chickens and elicit protective immune responses, overcoming the previous limitation where adequate immunity could not be achieved without sufficient replication.
3Adaptability or versatility
If existing fowl adenovirus serotypes are used, then vaccine vector functionality is achieved, but replication capacity is limited
Solution Approach 1:
The patent applies parameter changes by selecting and characterizing novel FAdV-4 and FAdV-10 serotypes with distinct replication properties compared to existing vaccine vectors. These parameter changes in viral serotype identity enable the vectors to maintain versatility for vaccine applications while achieving superior replication capacity (≥3 log10 viral titer), thus resolving the contradiction between adaptability and productivity.
Data Source
AI summary
A high level replication fowl adenovirus (FAdV) isolate capable of reaching a viral titer of at least 3 log 10 is described. Said FAdV is a non-pathogenic strain of fowl adenovirus serotype 4, identified as FAdV-4 ON1. Additionally, the present disclosure also provides a viral vector comprising the fowl adenovirus, which has inserted an exogenous nucleotide sequence coding for at least one antigenic site of a disease of concern, as well as a method for obtaining said viral vector and an immunogenic composition comprising the same.